Palisades Investment Partners, LLC Krystal Biotech, Inc. Transaction History
Palisades Investment Partners, LLC
- $237 Billion
- Q4 2024
A detailed history of Palisades Investment Partners, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Palisades Investment Partners, LLC holds 40,479 shares of KRYS stock, worth $7.13 Million. This represents 2.68% of its overall portfolio holdings.
Number of Shares
40,479
Previous 37,043
9.28%
Holding current value
$7.13 Million
Previous $6.74 Billion
5.95%
% of portfolio
2.68%
Previous 2.94%
Shares
3 transactions
Others Institutions Holding KRYS
# of Institutions
298Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$695 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$507 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$463 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$225 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$155 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.52B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...